TSWM
CDTX

Tyler-Stone Wealth Management’s Cidara Therapeutics CDTX Stock Holding History

Tyler-Stone Wealth Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-38
Closed -$1K – 847
2021
Q4 		$1K Buy
+38
New +$1.18K ﹤0.01% 840

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Tyler-Stone Wealth Management's CDTX Position: Q1 2022 in Review

Tyler-Stone Wealth Management sold out of Cidara Therapeutics (CDTX) in Q1 2022, closing a stake of 38 shares — an estimated $1K sold.

Tyler-Stone Wealth Management first reported a position in CDTX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 44 funds tracked by Wall St. Rank hold CDTX as of Q1 2022.

  • Tyler-Stone Wealth Management reported no remaining Cidara Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Tyler-Stone Wealth Management sold 38 Cidara Therapeutics shares in Q1 2022, an estimated $1K.
  • Tyler-Stone Wealth Management first reported a position in Cidara Therapeutics in Q4 2021 and held it in 1 quarter.
  • Tyler-Stone Wealth Management's Cidara Therapeutics position peaked at $1K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2022.

Based on Tyler-Stone Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.